Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
Open Access
- 4 October 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (9), 1342-1345
- https://doi.org/10.1038/bjc.2011.402
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 18 references indexed in Scilit:
- Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?Breast Cancer Research and Treatment, 2011
- A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast CancerCancer Investigation, 2010
- Ki67 in breast cancer: prognostic and predictive potentialThe Lancet Oncology, 2010
- Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence ScoreInternational Journal of Surgical Pathology, 2009
- Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 TrialJournal of Clinical Oncology, 2009
- Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With LetrozoleJournal of Clinical Oncology, 2008
- Histopathologic variables predict Oncotype DX™ Recurrence ScoreLaboratory Investigation, 2008
- Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 2008
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004